Citation Impact
Citing Papers
CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells
2012
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
2009 Standout
Infective Endocarditis
2005 Standout
Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection
2008
Cochrane Database of Systematic Reviews
2003 Standout
Cancer statistics, 2018
2018 Standout
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications
2015 Standout
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
2008
Birth Prevalence of Congenital Heart Disease Worldwide
2011 Standout
New insights into T cell biology and T cell‐directed therapy for autoimmunity, inflammation, and immunosuppression
2010
Posaconazole for the Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Subjects with HIV Infection
2007
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
New approaches for the treatment of bacterial vaginosis
1993
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates
2009 Standout
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
2007 Standout
Pneumococcal Disease among Human Immunodeficiency Virus-Infected Persons: Incidence, Risk Factors, and Impact of Vaccination
2001
Increase in Invasive Streptococcus Pneumoniae Infections in Children with Sickle Cell Disease since Pneumococcal Conjugate Vaccine Licensure
2010
The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease
2007
Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial
1999 Standout
Congenital infections
2002
A cytokine-mediated link between innate immunity, inflammation, and cancer
2007 Standout
Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection
2015
Noninherited Risk Factors and Congenital Cardiovascular Defects: Current Knowledge
2007
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
CRISPR–Cas9 genome engineering of primary CD4+ T cells for the interrogation of HIV–host factor interactions
2018 StandoutNobel
Streptococcus pneumoniae Endocarditis in Adults: A Multicenter Study in France in the Era of Penicillin Resistance (1991-1998)
2000
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
2008 Standout
Prophylactic administration of clindamycin 2 % vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo‐controlled double‐blind trial
1999
A New Equation to Estimate Glomerular Filtration Rate
2009 Standout
A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma
2006
Managing HIV/hepatitis C co-infection in the era of direct acting antivirals
2013
Screening of the Pan-African Natural Product Library Identifies Ixoratannin A-2 and Boldine as Novel HIV-1 Inhibitors
2015 StandoutNobel
Sensorineural hearing loss in children
2005 Standout
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
2009
Hepatitis C virus infection
2017
Interleukin‐10 in viral diseases and cancer: exiting the labyrinth?
2004
Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978–1997
1999
Intrauterine Infection and Preterm Delivery
2000 Standout
Leishmaniasis Worldwide and Global Estimates of Its Incidence
2012 Standout
Sickle-cell disease
2010 Standout
Homophily and co-occurrence patterns shape randomized trials agendas: illustration in antifungal agents
2011
Initiating Therapy: When to Start, What to Use
2008
Applications of CRISPR technologies in research and beyond
2016 StandoutNobel
Antiretroviral Drug Resistance Testing in Adult HIV‐1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel
2008
A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model
2013
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
2016 Standout
Computational design of orthogonal nucleoside kinases
2010 StandoutNobel
The Clinical Significance of Positive Blood Cultures in the 1990s: A Prospective Comprehensive Evaluation of the Microbiology, Epidemiology, and Outcome of Bacteremia and Fungemia in Adults
1997
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Guidelines for the Prevention of Intravascular Catheter-related Infections
2011 Standout
HIV-1 Neutralization Profile and Plant-Based Recombinant Expression of Actinohivin, an Env Glycan-Specific Lectin Devoid of T-Cell Mitogenic Activity
2010 StandoutNobel
Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials
2001
Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study
2004 Standout
Intensive Insulin Therapy in Critically Ill Patients
2001 Standout
Randomized, Comparative, Double-Blind, Double-Dummy, Multicenter Trial of Miconazole Buccal Tablet and Clotrimazole Troches for the Treatment of Oropharyngeal Candidiasis: Study of Miconazole Lauriad®Efficacy and Safety (SMiLES)
2010
Intensive Insulin Therapy in the Medical ICU
2006 Standout
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
2007 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?
2009
Treatment of Hepatitis C
2014
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
2017
Invasive Candidiasis
2015 Standout
A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1
2019 StandoutNobel
Posaconazole: A Next-Generation Triazole Antifungal
2007
Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN ‐free treatment and future perspectives
2016
Assessment of Leishmaniasis notification system in Santiago del Estero, Argentina, 1990-1993.
2001
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
Pneumococcal Virulence Factors: Structure and Function
2001
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Iatrogenic Contamination of Multidose Vials in Simulated Use
1990
Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
2000
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model
2017 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Maraviroc
2008
Perspectives on HCV: Current Therapeutic Regimens and Drug–Drug Interactions
2017
Viral Quasispecies Evolution
2012
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
2003 Standout
Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution
2010
Insertion Sequence 1515 in the ply Gene of a Type 1 Clinical Isolate of Streptococcus pneumoniae Abolishes Pneumolysin Expression
2007 StandoutNobel
Drug Prescribing in Renal Failure: Dosing Guidelines for Adults.
1988
Epitope-Specific CD8+T Lymphocytes Cross-Recognize Mutant Simian Immunodeficiency Virus (SIV) Sequences but Fail To Contain Very Early Evolution and Eventual Fixation of Epitope Escape Mutations during SIV Infection
2011
Works of Wayne Greaves being referenced
Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1–Infected Treatment-Experienced Patients
2010
Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211
2007
Pneumococcal Bacteremia in Adults: A 14-Year Experience in an Inner-City University Hospital
1995
Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment‐Naive Subjects with HIV‐1 Infection
2008
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
2015
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial
2013
Pneumococcal Sepsis and Meningitis in Adults With Sickle Cell Disease
1990
HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211
2007
A Multicenter Randomized Trial Evaluating Posaconazole versus Fluconazole for the Treatment of Oropharyngeal Candidiasis in Subjects with HIV/AIDS
2006
CONGENITAL RUBELLA SYNDROME IN THE UNITED STATES, 1970–1985
1989
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
2017
Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo
2009
A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects
2000
Streptococcal abscesses following diphtheria-tetanus toxoid-pertussis vaccination
1982
Clindamycin versus metronidazole in the treatment of bacterial vaginosis.
1988
Pneumococcal bacteremia in adults: differences between patients with and without human immunodeficiency virus infection
1997
Cefoxitin disposition during peritoneal dialysis
1981
In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject
2008